Future Implications and Research Directions Expanding Therapeutic Applications The comprehensive health benefits demonstrated by GLP-1 medications suggest expanding therapeutic applications beyond diabetes and obesity ^36
For stubborn abdominal fat specifically, tesamorelin has the strongest human evidence
Ozempic is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes treatment, administered as a once-weekly subcutaneous injection
Collectively, these factors may pre-activate the immune system and increase mitochondrial vulnerability, potentially rendering what would normally be a routine exercise into a trigger for an uncontrollable and amplified pathological cascade
Furthermore, while preclinical studies have demonstrated promising results, comprehensive clinical trials are necessary to validate the safety and efficacy of supersulfide-based therapies in human diseases
doi: 10.3390/ijms22073789